Ovarian Cancer Diagnostics Global Market Report 2024

The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.62 billion in 2023 to $2.82 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the historical timeframe can be ascribed to advancements in biomarker exploration and validation, increased adoption of transvaginal ultrasound, heightened awareness of BRCA gene mutations, intensified research on tumor markers, and the implementation of screening programs and guidelines.

The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated expansion in the forecasted period is linked to initiatives focused on early detection, a rising incidence of ovarian cancer, the integration of artificial intelligence (AI), personalized medicine approaches, the emergence of novel biomarkers, and the adoption of genomic and proteomic profiling. Key trends expected in the forecast period encompass the utilization of biosensor technologies for early detection, integration of digital pathology, innovations in imaging modalities, enhancements in imaging technologies, and progress in pathology techniques.

The anticipated increase in the prevalence of ovarian cancer is expected to drive the growth of the ovarian cancer diagnostics market in the foreseeable future. Ovarian cancer, characterized by the development of malignant tumors in the ovaries, essential for female reproductive functions, has witnessed a surge due to factors such as prolonged life expectancy, delayed childbearing, and shifts in lifestyle. This transformation underscores the importance of ovarian cancer diagnostics, which play a pivotal role in early detection and intervention. Early diagnosis facilitates timely treatment, leading to improved outcomes for patients. For example, data from the World Ovarian Cancer Coalition, a Canada-based non-profit organization, revealed that ovarian cancer affected 313,959 women globally in 2020. The projections indicate a 42% increase to 445,721 cases by 2040, with a corresponding 51% rise in the number of women succumbing to ovarian cancer, reaching 313,617. Hence, the growing prevalence of ovarian cancer is a key factor propelling the ovarian cancer diagnostics market.

The prevalence of gynecological cancer is also poised to contribute significantly to the growth of the ovarian cancer diagnostics market. Gynecologic cancer encompasses cancers originating in a woman's reproductive organs, and ovarian cancer diagnosis drugs play a crucial role in reducing its prevalence. These drugs contribute to the treatment and management of gynecological cancer, preventing recurrence and enhancing patient outcomes through diverse therapeutic approaches. The statistics from the World Ovarian Cancer Coalition further emphasize the impact, projecting a 42% increase in ovarian cancer cases from 313,959 in 2020 to 445,721 by 2040. Over the same period, there is anticipated to be a 51% rise in the number of women succumbing to ovarian cancer, reaching 313,617. Consequently, the substantial prevalence of gynecological cancer emerges as a driving force behind the growth of the ovarian cancer diagnostics market.

The ovarian cancer diagnostics market is witnessing a notable trend with the increasing adoption of advanced diagnostic technology. Companies in this market are actively incorporating advanced diagnostic technologies as a strategic move to maintain their competitive positions. An illustrative example is Hoffmann-La Roche AG, a pharmaceutical and healthcare company based in Switzerland. In November 2022, the company secured FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This groundbreaking immunohistochemistry (IHC)-based companion diagnostic test kit identifies ovarian cancer patients eligible for the prescription medication ELAHERE. The approval signifies a significant advancement in diagnostic capabilities, providing critical insights and detailed clinical information for improved disease management and patient outcomes.

Major players in the ovarian cancer diagnostics market are actively engaging in partnerships to foster product development and fortify their market positions. Collaborative efforts in this sector contribute to enhanced research, development, and commercialization by leveraging the combined expertise, resources, and networks of multiple entities. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, joined forces with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. This partnership focuses on the development and commercialization of ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen stands to benefit from upfront and milestone payments, along with double-digit royalties, while Takeda gains exclusive rights to develop and commercialize ELAHERE in Japan. This collaboration addresses an unmet need for individuals with platinum-resistant ovarian cancer, showcasing a shared commitment to advancing cancer treatment options on a global scale.

In September 2022, GENinCode PLC, a biotechnology company based in the UK specializing in genetic testing for assessing the risk of cardiovascular diseases, successfully completed the acquisition of Abcodia for a sum of $1.25 million. This strategic acquisition marks a significant expansion, diversification, and reinforcement of GENinCode's technological capabilities. The addition of Abcodia's advanced algorithm technology for the risk assessment of ovarian cancer (ROCA) enhances GENinCode's portfolio, particularly in the domain of early detection of ovarian cancer. Abcodia, also based in the UK, is recognized for its expertise in manufacturing biomarkers designed for the early identification of ovarian cancer. This acquisition underscores GENinCode's commitment to advancing its technology and expanding its offerings, positioning the company as a more comprehensive player in the field of genetic testing and diagnostics.

Major companies operating in the ovarian cancer diagnostics market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., The American Cancer Society, Myriad Genetics Inc., ArcherDX Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc.

North America was the largest region in the ovarian cancer diagnostic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of ovarian cancer diagnostic products comprise instruments, kits, and reagents. Instruments play a pivotal role in medical diagnostics, encompassing imaging devices such as ultrasound and MRI, blood tests utilizing markers such as CA-125 and HE4, as well as tissue sampling techniques including biopsy and laparoscopy. Various diagnostic methods, such as biopsy, blood tests, imaging, and others, are deployed to identify specific types of ovarian cancer, including epithelial tumors, germ cell tumors, stromal cell tumors, among others. These diagnostic tools find application across diverse end-users, including cancer diagnostic centers, hospital laboratories, and research institutes. The comprehensive array of diagnostic techniques contributes to accurate and targeted identification of ovarian cancer subtypes, facilitating tailored treatment approaches.

The ovarian cancer diagnostics market research report is one of a series of new reports that provides ovarian cancer diagnostics market statistics, including ovarian cancer diagnostics industry global market size, regional shares, competitors with a ovarian cancer diagnostics market share, detailed ovarian cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer diagnostics industry. This ovarian cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.